multiple sclerosis news

Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.

Benzinga.com · 1d

Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows

Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed increased disability improvement,

BioTechniques · 1d

Biomarkers for predicting multiple sclerosis progression identified

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the development of more personalized treatment strategies.

Reuters · 1d

Sanofi wins US approval for drug combination to treat multiple myeloma

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed,

GlobalData on MSN · 1d

Sanofi’s eyes approval after MS therapy slows disease progression by 31%

After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS patients.

MedPage Today2h

Women With MS Less Likely to Receive Treatment Than Men

Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

FierceBiotech1d

Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

PHILADELPHIA.Today on MSN18h

Local Multiple Sclerosis Advocate Honored With State Citation

Bucks County resident Joseph “Smiley” Terinoni was recently presented with a citation from the Pennsylvania House of ...

Medpage Today on MSN3d

Higher Comorbidity Burden in Multiple Sclerosis Tied to Worse Outcomes

Higher comorbidity burden among people with multiple sclerosis (MS) was associated with worse clinical outcomes, pooled trial ...

Medscape1d

High-Dose Vitamin D Linked to Lower Disease Activity in CIS

Vitamin D is linked to a 34% reduction in the relative risk for disease activity in patients with clinically isolated ...

2don MSN

Key biomarkers identified for predicting disability progression in multiple sclerosis

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

MedPage Today on MSN1d

Kids With MS May Have Better Outcomes When Started on High-Efficacy Treatment Early

Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

Medscape8d

Does Multiple Sclerosis Protect Against Alzheimer's?

Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...

The Lancet1d

Evobrutinib in multiple sclerosis: challenges and unmet goals

Available disease-modifying therapies can prevent relapses and relapse-associated worsening in people with multiple sclerosis by targeting autoimmunity through various mechanisms. However, these ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Related topics